Related Experiment Video
Updated: Aug 5, 2026
A Method for High Fidelity Optogenetic Control of Individual Pyramidal Neurons In vivo
Published on: September 2, 2013
Engineering a 660 nm-Responsive Optogenetic Inducer of Pyroptosis for Precision Cancer Therapy
Mengkai Zhang1, Zhichao Li1, Yonghao Ma2
1Medical Innovation Technology Transformation Center, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Institute for Advanced Study, Synthetic Biology Research Center, Shenzhen University, Shenzhen, People's Republic of China.
Abstract:
Inducing tumor cell pyroptosis represents a promising anticancer strategy; however, uncontrolled pyroptosis not only restricts the production of viral delivery vectors but also poses a risk of systemic damage, thereby limiting the translational application of pyroptosis-based therapies. The development of genetic tools that enable precise spatiotemporal control over pyroptosis remains challenging. To address this, we developed PyroRACS, a bioorthogonal optogenetic inducer for precise pyroptosis induction. PyroRACS utilizes an engineered red-light-activatable Cre-ON genetic switch (RACS) to drive the expression of the gasdermin D N-terminal domain, enabling tunable initiation of pyroptosis without relying on endogenous signaling pathways. We validated robust pyroptosis induction by PyroRACS in multiple cell lines. PyroRACS exhibited high controllability by selectively ablating cancer cells in vitro with precise spatiotemporal resolution. Moreover, its superior controllability enabled the production of the adenovirus vector and allowed "all-in-one" delivery of PyroRACS. In a tumor-bearing mouse model, spatially restricted induction of pyroptosis by PyroRACS resulted in effective tumor suppression, with no detectable systemic toxicity observed under the tested conditions. Collectively, PyroRACS provides a novel optogenetic tool for precise manipulation of pyroptosis, facilitating fundamental research and advancing pyroptosis-based precision oncology therapeutics.
Insights
Researchers developed PyroRACS, a novel optogenetic tool for precise control of pyroptosis, a promising cancer therapy. This innovation enables targeted tumor cell killing with reduced systemic damage and improved viral vector production.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Pyroptosis is a promising anticancer strategy, but its uncontrolled induction poses risks.
- Lack of precise spatiotemporal control limits pyroptosis-based therapies.
- Developing genetic tools for controlled pyroptosis is crucial for clinical translation.
Purpose of the Study:
- To develop a novel bioorthogonal optogenetic tool for precise spatiotemporal control of pyroptosis.
- To enable tunable pyroptosis induction independent of endogenous pathways.
- To advance pyroptosis-based precision oncology therapeutics.
Main Methods:
- Development of PyroRACS, a red-light-activatable Cre-ON genetic switch (RACS).
- RACS drives expression of the gasdermin D N-terminal domain for pyroptosis induction.
- Validation in multiple cell lines and a tumor-bearing mouse model.
Main Results:
- PyroRACS demonstrated robust and controllable pyroptosis induction in vitro.
- Selective cancer cell ablation with precise spatiotemporal resolution was achieved.
- Effective tumor suppression with no detectable systemic toxicity in vivo.
Conclusions:
- PyroRACS offers a novel optogenetic tool for precise pyroptosis manipulation.
- This tool facilitates fundamental research in pyroptosis.
- PyroRACS advances the development of pyroptosis-based precision oncology therapeutics.
